An interventional study of Digital Transformation Network (DTN) Program in Inflammatory Bowel Disease (IBD), sponsored by Icahn School of Medicine at Mount Sinai. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 3 under way, none of them phase 3. Inflammatory Bowel Diseases · Icahn School of Medicine at Mount Sinai.
Among the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 8th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →2 of the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2022.
This study's enrollment of 659 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 110 across the 6 interventional studies, 94 across the 5 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
1 of the studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07207200Icahn School of Medicine at Mount SinaiImpact of Morning Light Therapy in IBD | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potential to bridge this gap, but the question remains as to how to translate it to mainstream practice while providing individualized recommendations to improve population health across organizations. Through the creation of a Digital Transformation Network (DTN) for Inflammatory Bowel Disease (IBD), the study team plans to reduce digital disparities and scientifically test the impact of these technologies in a clinical trial in three CTSA sites catering to diverse populations and communities.
Delivery of healthcare has been traditionally limited to in-person office visits or hospitalizations, while patients spent the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes ePRO has the potential to bridge this gap, but it is unclear how to implement in a mainstream clinical practice that can lead to high-level patient and provider adoption. Through the creation of a Digital Transformation Network (DTN) for Inflammatory Bowel Disease (IBD), the study team plans to reduce digital disparities and scientifically address the evidence gap of digital health interventions across populations and communities.
AIM I. Unify existing digital assets (mobile app, ePROs, assessment for digital disparities and behavioral health, referral to IBD home and health education) into an IBD Digital Therapeutics Toolkit and integrate with EHRs at 3 CTSA hubs. Hypothesis: Integration with EHRs will lead to higher adoption by providers and limit disruption of workflow.
AIM II: Establish baseline levels of digital connectivity, disease control, quality of life and care metrics in cohorts at the three IBD centers. Hypothesis: A multipronged approach of assessment through text, phone, an app, and in-person will yield higher adoption.
AIM III. Implement and evaluate precision-matched interventions (digital skills, social determinants, behavioral health, monitoring through apps, and referral to interdisciplinary care) among 1500 patients with IBD using a stepped-wedge, cluster- randomized trial. Hypothesis: Medical homes supported by a unified platform will translate to sustainable improvement in population health outcomes. Analyze the Impact of DTN interventions. The primary outcome will be the improvement of the percentage of patients in DTN in disease control and decrease in urgent care utilization (emergency department visits and hospitalization days) across the three CTSA sites.
AIM IV. Support sustainability and dissemination across CTSA sites. Hypothesis: The patient- centric DTN will be sustainable through alignment with value-based healthcare.
Anticipated Impact: About 2 million Americans suffer from IBD and many more with chronic inflammatory diseases. The study team hopes that this study will help the study team build an evidence-based approach to determine whether digital medicine can engage a diverse group of patients and improve outcomes; and if yes, how it can be reproduced and replicated across different settings to address theT3 and T4 translational gaps.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Condition or disease that, in the opinion of the investigators, may make it exceedingly difficult for the patient to use DTN, including, but not limited to, advanced dementia.
IBD patients at the 3 sites will be sent a message to their Smartphone
Behavioral: Digital Transformation Network (DTN) Program
Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
Proportion of Participants in Disease Control
Proportion of participants in disease control at assessments at end of control period (week 0) and at end of intervention period (week 52). Disease control is defined by normalization of inflammatory markers and ePROs (PRO2\<8 and PRO3\<13). PRO2 measures stool frequency and bleeding while PRO3 measures the number of liquid or soft stools, abdominal pain and general well-being. Inflammatory markers including Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Fecal Calprotectin will be dichotomized using cut-offs of \<30mm/hr, \<5mg/L and \<250 μg/g respectively for normal values.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Change in Number of Unplanned Acute Care
Change in number of unplanned acute care. Unplanned acute care is defined as the number of ED visits and hospitalizations days 12 months before the intervention and the last 12 months of DTN intervention.
Time frame: 12 months before intervention and 12 months after intervention
Northstar Digital Literacy Assessment
For participants who screened positive for needing assistance with digital connectivity and skills. Digital skills and connectivity will be assessed using the Northstar digital literacy assessment. A 17-item rating scale, with full score from 0 to 100, with score 85% or above achieve a passing score.
Time frame: week 52
Digital Disparities Module
For participants who screened positive for needing assistance with digital connectivity and skills. The digital disparities module is still in development through SBIR. The digital disparities module will assess the impact of digital disparities module in improving digital skills and access to Internet using previously developed digital disparities assessment instrument. The scale for the digital disparities assessment full scale from 0 - 100 where a higher score indicates the patient has a higher level of disparity in digital connectivity, digital skills and digital usage.
Time frame: 1 year after enrollment
Change in Overall Health Numeric Rating Scale [OHNRS]
OHNRS - Full scale from 0 to 10, higher score indicates better health outcomes
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Change in PROMIS Global Scales
Change in PROMIS Global scales is a 14-item measure that is part of the PROMIS Social Function. The measure refers to social roles, such as work and family responsibilities, and more discretionary social activities, such as leisure activity and relationships with friends. standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Change in Patient Health Questionnaire (PHQ-4)
The Patient Health Questionnaire (PHQ)-4 s a 4 item inventory. Anxiety subscale from 0-6, depression subscale from 0-6, with full scale from 0-12, higher score indicates more symptoms.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Change in Patient Health Questionnaire (PHQ-8)
The Questionnaire Type 9 for Depression (PHQ-8) is a self-administered instrument. Full scale from 0-24, with higher score indicating more severe symptoms. As needed.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Change in Generalized Anxiety Disorder Scale (GAD-7)
The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire. Full scale from 0-21, with higher score indicating more symptoms. As needed.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Improvement in Mucosal Healing
Improvement in mucosal healing will be defined as the absence of inflammation on endoscopy (scoring systems) or imaging notes collected from EHR.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
Proportion of Participants With Medication Adherence
Proportion of participants with medication adherence will be assessed with the Visual Analog Scale (VAS) using \<80% cut-off to designate non-adherence. Full Scale from 0 to 100 with higher score indicating more adherence.
Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
System Usability Scale (SUS)
The system usability scale (SUS) is a 10-item Likert scale questionnaire. The range of scores is from 0 - 100 where a SUS score above 68 is considered average.
Time frame: End of Intervention Period (Week 52)
Net Promoter Score
The Net Promoter is a 10 point scale and the full score ranges from -100 to 100 where a higher score translates to higher satisfaction with a product.
Time frame: End of Intervention Period (Week 52)
Enrollment began May 2022 at IBD Centers at Icahn School of Medicine at Mount Sinai, Cleveland Clinic and UC Davis. Due to significant delays, enrollment at all sites enrolled as soon as possible at the same time and a cluster randomized study with a stepped wedge study design was not utilized.
| Milestone | Icahn School of Medicine at Mount Sinai | Cleveland Clinic | UC Davis |
|---|---|---|---|
| Started | 395 | 145 | 119 |
| Completed | 382 | 135 | 106 |
| Not completed | 13 | 10 | 13 |
| Withdrew: Withdrawal by subject | 13 | 10 | 13 |
| Milestone | Icahn School of Medicine at Mount Sinai | Cleveland Clinic | UC Davis |
|---|---|---|---|
| Started | 382 | 135 | 106 |
| Completed | 238 | 98 | 75 |
| Not completed | 144 | 37 | 31 |
| Withdrew: Withdrawal by subject | 92 | 25 | 23 |
| Withdrew: Lost to follow-up | 52 | 12 | 8 |
Proportion of participants in disease control at assessments at end of control period (week 0) and at end of intervention period (week 52). Disease control is defined by normalization of inflammatory markers and ePROs (PRO2\<8 and PRO3\<13). PRO2 measures stool frequency and bleeding while PRO3 measures the number of liquid or soft stools, abdominal pain and general well-being. Inflammatory markers including Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Fecal Calprotectin will be dichotomized using cut-offs of \<30mm/hr, \<5mg/L and \<250 μg/g respectively for normal values.
| proportion of participants | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 0.43 ± 0.03 |
| End of Intervention Period (Week 52) | 0.55 ± 0.02 | — |
Change in number of unplanned acute care. Unplanned acute care is defined as the number of ED visits and hospitalizations days 12 months before the intervention and the last 12 months of DTN intervention.
| events | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| 12 months before intervention | — | 3.66 ± 9.50 |
| 12 months after intervention | 1.41 ± 4.33 | — |
For participants who screened positive for needing assistance with digital connectivity and skills. Digital skills and connectivity will be assessed using the Northstar digital literacy assessment. A 17-item rating scale, with full score from 0 to 100, with score 85% or above achieve a passing score.
No measurements were reported for this outcome.
For participants who screened positive for needing assistance with digital connectivity and skills. The digital disparities module is still in development through SBIR. The digital disparities module will assess the impact of digital disparities module in improving digital skills and access to Internet using previously developed digital disparities assessment instrument. The scale for the digital disparities assessment full scale from 0 - 100 where a higher score indicates the patient has a higher level of disparity in digital connectivity, digital skills and digital usage.
No measurements were reported for this outcome.
OHNRS - Full scale from 0 to 10, higher score indicates better health outcomes
| score on a scale | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 6.08 ± 1.80 |
| End of Intervention Period (Week 52) | 6.99 ± 1.81 | — |
Change in PROMIS Global scales is a 14-item measure that is part of the PROMIS Social Function. The measure refers to social roles, such as work and family responsibilities, and more discretionary social activities, such as leisure activity and relationships with friends. standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.
| T score | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 45.63 ± 9.13 |
| End of Intervention Period (Week 52) | 46.30 ± 8.30 | — |
The Patient Health Questionnaire (PHQ)-4 s a 4 item inventory. Anxiety subscale from 0-6, depression subscale from 0-6, with full scale from 0-12, higher score indicates more symptoms.
| score on a scale | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 3.51 ± 3.08 |
| End of Intervention Period (Week 52) | 1.47 ± 1.80 | — |
The Questionnaire Type 9 for Depression (PHQ-8) is a self-administered instrument. Full scale from 0-24, with higher score indicating more severe symptoms. As needed.
| score on a scale | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 13.12 ± 9.03 |
| End of Intervention Period (Week 52) | 2.90 ± .04 | — |
The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire. Full scale from 0-21, with higher score indicating more symptoms. As needed.
| score on a scale | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 7.01 ± 5.16 |
| End of Intervention Period (Week 52) | 2.35 ± 2.91 | — |
Improvement in mucosal healing will be defined as the absence of inflammation on endoscopy (scoring systems) or imaging notes collected from EHR.
No measurements were reported for this outcome.
Proportion of participants with medication adherence will be assessed with the Visual Analog Scale (VAS) using \<80% cut-off to designate non-adherence. Full Scale from 0 to 100 with higher score indicating more adherence.
| proportion of participants | Digital Transformation Network (DTN) Program | Control Arm |
|---|---|---|
| End of Control Period (Week 0) | — | 0.91 ± 0.01 |
| End of Intervention Period (Week 52) | 0.93 ± 0.01 | — |
The system usability scale (SUS) is a 10-item Likert scale questionnaire. The range of scores is from 0 - 100 where a SUS score above 68 is considered average.
| score on a scale | Digital Transformation Network (DTN) Program |
|---|---|
| System Usability Scale (SUS) | 37.56 ± 14.51 |
The Net Promoter is a 10 point scale and the full score ranges from -100 to 100 where a higher score translates to higher satisfaction with a product.
| score on a scale | Digital Transformation Network (DTN) Program |
|---|---|
| Net Promoter Score | 7.63 ± 2.56 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Digital Transformation Network (DTN) Program | 0/659 (0%) | 0/659 (0%) | 0/659 (0%) |
| Control Arm | 0/659 (0%) | 0/659 (0%) | 0/659 (0%) |
| Age, Continuous(years) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Mean | 41.27 ± 15.54 | 44.78 ± 13.99 | 46.72 ± 16.70 | 43.02 ± 15.57 |
| Sex: Female, Male(Participants) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Female | 236 | 107 | 68 | 411 |
| Male | 159 | 38 | 51 | 248 |
| Ethnicity (NIH/OMB)(Participants) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 5 | 9 | 14 |
| Not Hispanic or Latino | 17 | 133 | 91 | 241 |
| Unknown or Not Reported | 378 | 7 | 19 | 404 |
| Race/Ethnicity, Customized(Participants) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Amerian Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 18 | 2 | 4 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 23 | 10 | 4 | 37 |
| White | 275 | 125 | 94 | 494 |
| More than one race | 3 | 1 | 0 | 4 |
| Other | 58 | 0 | 5 | 63 |
| Unknown or Not Reported | 18 | 6 | 12 | 36 |
| ED visits(ED visits) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Mean | 0.70 ± 1.63 | 1.36 ± 3.09 | 0.96 ± 2.02 | 0.89 ± 2.11 |
| Hospital stays(days) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Mean | 2.63 ± 8.11 | 3.60 ± 10.63 | 2.24 ± 5.73 | 2.77 ± 8.35 |
| OHNRS(score on a scale) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Mean | 6.24 ± 1.71 | 5.80 ± 1.77 | 5.95 ± 2.05 | 6.08 ± 1.80 |
| PROMIS(score on a scale) | Icahn School of Medicine at Mount Sinai | Cleveland Clinici | UC Davis | Total |
|---|---|---|---|---|
| Mean | 32.83 ± 7.16 | 31.26 ± 7.04 | 31.33 ± 8.51 | 32.18 ± 7.44 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from May 2022 to primary completion in Mar 2025, 34 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 34 months is above that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →